Trials / Conditions / Acquired Bleeding Disorder

Acquired Bleeding Disorder

26 registered clinical trials studyying Acquired Bleeding Disorder.

Status	Trial	Sponsor	Phase
Completed	Observational Study on the Use of NovoSeven® for Haemostatic Treatment of Bleeding Episodes in Patients With A NCT01285089	Novo Nordisk A/S	—
Completed	Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese Volunteers NCT01153997	Novo Nordisk A/S	Phase 1
Completed	Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing NCT00914589	Novo Nordisk A/S	Phase 2
Completed	Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany NCT00697320	Novo Nordisk A/S	—
Withdrawn	Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma NCT00323570	Novo Nordisk A/S	Phase 3
Completed	Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects NCT01561417	Novo Nordisk A/S	Phase 1
Completed	Factor VIIa in Acute Intracerebral Haemorrhage NCT00266006	Novo Nordisk A/S	Phase 2
Completed	Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypas NCT02239146	Novo Nordisk A/S	Phase 1
Terminated	Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding NCT00184548	Novo Nordisk A/S	Phase 3
Completed	Recombinant Factor VIIa in Acute Intracerebral Haemorrhage NCT00127283	Novo Nordisk A/S	Phase 3
Completed	Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury NCT00123591	Novo Nordisk A/S	Phase 2
Completed	Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues Afte NCT00124293	Novo Nordisk A/S	—
Terminated	Use of Activated Recombinant Human Factor VII in Cardiac Surgery NCT00154427	Novo Nordisk A/S	Phase 2
Completed	Use of Activated Recombinant FVII in Spinal Surgery NCT00102037	Novo Nordisk A/S	Phase 2
Completed	Use of NovoSeven® in Active Variceal Bleeding NCT00154492	Novo Nordisk A/S	Phase 2
Completed	Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction NCT01601457	Novo Nordisk A/S	Phase 2
Completed	Recombinant Factor VIIa in Acute Intracerebral Haemorrhage NCT00426803	Novo Nordisk A/S	Phase 2
Terminated	Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following H NCT01564563	Novo Nordisk A/S	Phase 2
Completed	Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients NCT01563523	Novo Nordisk A/S	Phase 2
Completed	Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Diseas NCT01562574	Novo Nordisk A/S	Phase 3
Completed	Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth NCT01563445	Novo Nordisk A/S	Phase 2
Completed	Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage NCT01566786	Novo Nordisk A/S	Phase 2
Completed	Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transpla NCT01563458	Novo Nordisk A/S	Phase 2
Completed	Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever NCT01601613	Novo Nordisk A/S	Phase 2
Completed	Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatec NCT01562821	Novo Nordisk A/S	Phase 2
Completed	Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following A NCT01562158	Novo Nordisk A/S	Phase 2